A citation-based method for searching scientific literature

T Forst, R Guthrie, R Goldenberg, J Yee, U Vijapurkar, G Meininger, P Stein. Diabetes Obes Metab 2014
Times Cited: 192







List of co-cited articles
896 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial.
J P H Wilding, G Charpentier, P Hollander, G González-Gálvez, C Mathieu, F Vercruysse, K Usiskin, G Law, S Black, W Canovatchel,[...]. Int J Clin Pract 2013
230
70


Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.
K Stenlöf, W T Cefalu, K-A Kim, M Alba, K Usiskin, C Tong, W Canovatchel, G Meininger. Diabetes Obes Metab 2013
427
62

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial.
William T Cefalu, Lawrence A Leiter, Kun-Ho Yoon, Pablo Arias, Leo Niskanen, John Xie, Dainius A Balis, William Canovatchel, Gary Meininger. Lancet 2013
500
56

Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial.
Guntram Schernthaner, Jorge L Gross, Julio Rosenstock, Michael Guarisco, Min Fu, Jacqueline Yee, Masato Kawaguchi, William Canovatchel, Gary Meininger. Diabetes Care 2013
365
55

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
51

Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study.
Lawrence A Leiter, Kun-Ho Yoon, Pablo Arias, Gisle Langslet, John Xie, Dainius A Balis, Dawn Millington, Frank Vercruysse, William Canovatchel, Gary Meininger. Diabetes Care 2015
170
40

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease.
J-F Yale, G Bakris, B Cariou, D Yue, E David-Neto, L Xi, K Figueroa, E Wajs, K Usiskin, G Meininger. Diabetes Obes Metab 2013
355
36

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
35

Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study.
Kaj Stenlöf, William T Cefalu, Kyoung-Ah Kim, Esteban Jodar, Maria Alba, Robert Edwards, Cindy Tong, William Canovatchel, Gary Meininger. Curr Med Res Opin 2014
120
33

Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes.
B Bode, K Stenlöf, S Harris, D Sullivan, A Fung, K Usiskin, G Meininger. Diabetes Obes Metab 2015
142
33

Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.
Hans-Ulrich Häring, Ludwig Merker, Elke Seewaldt-Becker, Marc Weimer, Thomas Meinicke, Uli C Broedl, Hans J Woerle. Diabetes Care 2014
251
33

Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes.
Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Kenneth W Mahaffey, Greg Fulcher, Kirk Ways, Mehul Desai, Wayne Shaw, George Capuano, Maria Alba,[...]. Diabetes Care 2015
156
31


Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial.
Bruce Bode, Kaj Stenlöf, Daniel Sullivan, Albert Fung, Keith Usiskin. Hosp Pract (1995) 2013
166
31

Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.
Hans-Ulrich Häring, Ludwig Merker, Elke Seewaldt-Becker, Marc Weimer, Thomas Meinicke, Hans J Woerle, Uli C Broedl. Diabetes Care 2013
258
30

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.
Julio Rosenstock, Naresh Aggarwal, David Polidori, Yue Zhao, Deborah Arbit, Keith Usiskin, George Capuano, William Canovatchel. Diabetes Care 2012
316
29

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial.
Michael Roden, Jianping Weng, Jens Eilbracht, Bruno Delafont, Gabriel Kim, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2013
296
29


Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.
J-F Yale, G Bakris, B Cariou, J Nieto, E David-Neto, D Yue, E Wajs, K Figueroa, J Jiang, G Law,[...]. Diabetes Obes Metab 2014
157
27





Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.
Anthony H Barnett, Ambrish Mithal, Jenny Manassie, Russell Jones, Henning Rattunde, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2014
345
24


Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes.
H J Lambers Heerspink, D de Zeeuw, L Wie, B Leslie, J List. Diabetes Obes Metab 2013
419
23

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N Engl J Med 2016
23

Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension.
Ilkka Tikkanen, Kirsi Narko, Cordula Zeller, Alexandra Green, Afshin Salsali, Uli C Broedl, Hans J Woerle. Diabetes Care 2015
271
22

Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.
Martin Ridderstråle, Knut Robert Andersen, Cordula Zeller, Gabriel Kim, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2014
232
21

Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin.
Ralph A DeFronzo, Andrew Lewin, Sanjay Patel, Dacheng Liu, Renee Kaste, Hans J Woerle, Uli C Broedl. Diabetes Care 2015
199
21

Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin.
Jan Bolinder, Östen Ljunggren, Joel Kullberg, Lars Johansson, John Wilding, Anna Maria Langkilde, Jennifer Sugg, Shamik Parikh. J Clin Endocrinol Metab 2012
470
21


Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.
J Bolinder, Ö Ljunggren, L Johansson, J Wilding, A M Langkilde, C D Sjöström, J Sugg, S Parikh. Diabetes Obes Metab 2014
280
20

Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial.
Michael A Nauck, Stefano Del Prato, Juris J Meier, Santiago Durán-García, Katja Rohwedder, Martina Elze, Shamik J Parikh. Diabetes Care 2011
365
20


Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.
John P H Wilding, Vincent Woo, Norman G Soler, Andrea Pahor, Jennifer Sugg, Katja Rohwedder, Shamik Parikh. Ann Intern Med 2012
314
20

Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea.
L Ji, P Han, Y Liu, G Yang, N K Dieu Van, U Vijapurkar, R Qiu, G Meininger. Diabetes Obes Metab 2015
53
37

Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis.
William L Baker, Lindsay R Smyth, Daniel M Riche, Emily M Bourret, Kevin W Chamberlin, William B White. J Am Soc Hypertens 2014
259
19

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.
Silvio E Inzucchi, Richard M Bergenstal, John B Buse, Michaela Diamant, Ele Ferrannini, Michael Nauck, Anne L Peters, Apostolos Tsapas, Richard Wender, David R Matthews. Diabetes Care 2015
19


Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis.
Despoina Vasilakou, Thomas Karagiannis, Eleni Athanasiadou, Maria Mainou, Aris Liakos, Eleni Bekiari, Maria Sarigianni, David R Matthews, Apostolos Tsapas. Ann Intern Med 2013
514
19


Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.
Jason H Y Wu, Celine Foote, Juuso Blomster, Tadashi Toyama, Vlado Perkovic, Johan Sundström, Bruce Neal. Lancet Diabetes Endocrinol 2016
271
19


Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
18

Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial.
Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Kenneth W Mahaffey, Greg Fulcher, Peter Stein, Mehul Desai, Wayne Shaw, Joel Jiang, Frank Vercruysse,[...]. Am Heart J 2013
240
17


Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
17

Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study.
Linong Ji, Jianhua Ma, Hongmei Li, Traci A Mansfield, Caroline L T'joen, Nayyar Iqbal, Agata Ptaszynska, James F List. Clin Ther 2014
108
16


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.